229 related articles for article (PubMed ID: 31717492)
1. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
[TBL] [Abstract][Full Text] [Related]
2. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
Dale T; Clarke PA; Esdar C; Waalboer D; Adeniji-Popoola O; Ortiz-Ruiz MJ; Mallinger A; Samant RS; Czodrowski P; Musil D; Schwarz D; Schneider K; Stubbs M; Ewan K; Fraser E; TePoele R; Court W; Box G; Valenti M; de Haven Brandon A; Gowan S; Rohdich F; Raynaud F; Schneider R; Poeschke O; Blaukat A; Workman P; Schiemann K; Eccles SA; Wienke D; Blagg J
Nat Chem Biol; 2015 Dec; 11(12):973-980. PubMed ID: 26502155
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional Responses to IFN-γ Require Mediator Kinase-Dependent Pause Release and Mechanistically Distinct CDK8 and CDK19 Functions.
Steinparzer I; Sedlyarov V; Rubin JD; Eislmayr K; Galbraith MD; Levandowski CB; Vcelkova T; Sneezum L; Wascher F; Amman F; Kleinova R; Bender H; Andrysik Z; Espinosa JM; Superti-Furga G; Dowell RD; Taatjes DJ; Kovarik P
Mol Cell; 2019 Nov; 76(3):485-499.e8. PubMed ID: 31495563
[TBL] [Abstract][Full Text] [Related]
4. CDK8/19 Mediator kinases potentiate induction of transcription by NFκB.
Chen M; Liang J; Ji H; Yang Z; Altilia S; Hu B; Schronce A; McDermott MSJ; Schools GP; Lim CU; Oliver D; Shtutman MS; Lu T; Stark GR; Porter DC; Broude EV; Roninson IB
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10208-10213. PubMed ID: 28855340
[TBL] [Abstract][Full Text] [Related]
5. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
Hofmann MH; Mani R; Engelhardt H; Impagnatiello MA; Carotta S; Kerenyi M; Lorenzo-Herrero S; Böttcher J; Scharn D; Arnhof H; Zoephel A; Schnitzer R; Gerstberger T; Sanderson MP; Rajgolikar G; Goswami S; Vasu S; Ettmayer P; Gonzalez S; Pearson M; McConnell DB; Kraut N; Muthusamy N; Moll J
Mol Cancer Ther; 2020 Apr; 19(4):1018-1030. PubMed ID: 32024684
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Cdk8/Cdk19 Activity Promotes Treg Cell Differentiation and Suppresses Autoimmune Diseases.
Guo Z; Wang G; Lv Y; Wan YY; Zheng J
Front Immunol; 2019; 10():1988. PubMed ID: 31552016
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-Dependent Kinases 8 and 19 Regulate Host Cell Metabolism during Dengue Virus Serotype 2 Infection.
Butler M; Chotiwan N; Brewster CD; DiLisio JE; Ackart DF; Podell BK; Basaraba RJ; Perera R; Quackenbush SL; Rovnak J
Viruses; 2020 Jun; 12(6):. PubMed ID: 32560467
[TBL] [Abstract][Full Text] [Related]
9. CDK8 Kinase Activity Promotes Glycolysis.
Galbraith MD; Andrysik Z; Pandey A; Hoh M; Bonner EA; Hill AA; Sullivan KD; Espinosa JM
Cell Rep; 2017 Nov; 21(6):1495-1506. PubMed ID: 29117556
[TBL] [Abstract][Full Text] [Related]
10. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
[TBL] [Abstract][Full Text] [Related]
11. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.
Zhang L; Cheng C; Li J; Wang L; Chumanevich AA; Porter DC; Mindich A; Gorbunova S; Roninson IB; Chen M; McInnes C
J Med Chem; 2022 Feb; 65(4):3420-3433. PubMed ID: 35114084
[TBL] [Abstract][Full Text] [Related]
12. Ergosterol analogs as inhibitors of cyclin dependent kinase 8.
Siapkaras PD; Solum EJ
Steroids; 2022 Feb; 178():108965. PubMed ID: 35065996
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.
Schiemann K; Mallinger A; Wienke D; Esdar C; Poeschke O; Busch M; Rohdich F; Eccles SA; Schneider R; Raynaud FI; Czodrowski P; Musil D; Schwarz D; Urbahns K; Blagg J
Bioorg Med Chem Lett; 2016 Mar; 26(5):1443-51. PubMed ID: 26852363
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.
Czodrowski P; Mallinger A; Wienke D; Esdar C; Pöschke O; Busch M; Rohdich F; Eccles SA; Ortiz-Ruiz MJ; Schneider R; Raynaud FI; Clarke PA; Musil D; Schwarz D; Dale T; Urbahns K; Blagg J; Schiemann K
J Med Chem; 2016 Oct; 59(20):9337-9349. PubMed ID: 27490956
[TBL] [Abstract][Full Text] [Related]
15. HIV Transcription Is Independent of Mediator Kinases.
Cary DC; Rheinberger M; Rojc A; Peterlin BM
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):710-717. PubMed ID: 31044597
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer.
Offermann A; Joerg V; Becker F; Roesch MC; Kang D; Lemster AL; Tharun L; Behrends J; Merseburger AS; Culig Z; Sailer V; Brägelmann J; Kirfel J; Perner S
Am J Pathol; 2022 May; 192(5):813-823. PubMed ID: 35181333
[TBL] [Abstract][Full Text] [Related]
17. Identification of target genes for the CDK subunits of the Mediator complex.
Tsutsui T; Fukasawa R; Tanaka A; Hirose Y; Ohkuma Y
Genes Cells; 2011 Dec; 16(12):1208-18. PubMed ID: 22117896
[TBL] [Abstract][Full Text] [Related]
18. The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs.
Sharko AC; Lim CU; McDermott MSJ; Hennes C; Philavong KP; Aiken T; Tatarskiy VV; Roninson IB; Broude EV
Cells; 2021 Jan; 10(1):. PubMed ID: 33445730
[TBL] [Abstract][Full Text] [Related]
19. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
20. Mediator kinase inhibition reverses castration resistance of advanced prostate cancer.
Li J; Hilimire TA; Liu Y; Wang L; Liang J; Gyorffy B; Sikirzhytski V; Ji H; Zhang L; Cheng C; Ding X; Kerr KR; Dowling CE; Chumanevich AA; Mack ZT; Schools GP; Lim CU; Ellis L; Zi X; Porter DC; Broude EV; McInnes C; Wilding G; Lilly MB; Roninson IB; Chen M
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38546787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
